Delivery Order SPE2DB22D3010-SPE2DB25FP3KT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,703.95 to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 10-320 mg tablets (30-count units) on August 22, 2025, with completion targeted for August 25, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency has awarded a delivery order valued at $8,336.56 to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count packages). This firm fixed-price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. Amlodipine-Valsartan is a combination antihypertensive medication used in the treatment...
- The Defense Logistics Agency awarded a delivery order valued at $1,214.05 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90s, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $5,582.42 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This non-competitive delivery order utilizes firm fixed pricing and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,182.88 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Valsartan-HCZ 160-25 mg tablets in a quantity of 90 units. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,362.54 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on August 18, 2025, with completion expected by August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open contracting vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,054.55 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCZ 160-25 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's substantial pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $6,356.18 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,542.97 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. As a child delivery order under a...
- The Defense Logistics Agency awarded a $10,187.12 delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, competitively awarded delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The contractor, headquartered in Conshohocken, Pennsylvania, will perform the delivery at this same location. This award falls...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3KTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,700.58 to AmerisourceBergen Drug Corp for Amlodipine-Valsartan 5-160 mg tablets (30-count) on September 8, 2025, with a completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance. The award represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The SPE2DX vehicle functions as a comprehensive global pharmaceutical support contract enabling the company to supply a broad range of pharmaceutical products and medical supplies to support Defense Health Agency and other government healthcare systems worldwide. This delivery order for the antihypertensive combination medication reflects the company's role in fulfilling routine pharmaceutical supply needs within the broader defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/8/25 |